PF 5230905
Alternative Names: ATN-192; PF-05230905Latest Information Update: 22 Jun 2018
At a glance
- Originator Ablynx
- Class Antibodies; Antirheumatics; Proteins
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 19 Jun 2018 Ablynx has been acquired by Sanofi
- 16 Jul 2016 No recent reports of development identified for phase-I development in Rheumatoid-arthritis(In volunteers) in USA (IV)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Rheumatoid-arthritis(In volunteers) in USA (SC)